John A. Bartholdson
CIK 1382909 · Chairman · last filed 2026-06-04
John A. Bartholdson is a Chairman who has filed 33 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for BVS, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$2.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $143.7M across reported positions. 16 SEC filings were submitted jointly with Juniper Investment Company, LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LINC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
540 MADISON AVENUE, 25TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BVS | Director | 7,051,259 | $13.49 | $95.12M | $6.60M | 14 | 2026-06-04 |
| OFIX | 10%+ Owner | 45,426 | $9.59 | $435.6K | $7.77M | 1 | 2026-05-29 |
| LINC | Chairman | 2,150,769 | $22.37 | $48.11M | -$17.27M | 10 | 2026-05-08 |
| Obagi Medical Products, Inc. (OMPI) Delisted | Director | 17,953 | — | — | $0 | 7 | 2012-06-08 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | BVS | Mixed | +32,282 | $0 | EDGAR |
| 2026-05-29 | OFIX | Sell (S) | +726,000 | $7.77M | EDGAR |
| 2026-05-08 | LINC | Grant (A) | +3,515 | $155.0K | EDGAR |
| 2025-06-10 | BVS | Exer (M) | +7,575 | $0 | EDGAR |
| 2025-06-05 | BVS | Mixed | +26,493 | $0 | EDGAR |
| 2025-05-09 | LINC | Grant (A) | +5,628 | $105.0K | EDGAR |
| 2025-03-04 | LINC | Sell (S) | −826,632 | -$15.02M | EDGAR |
| 2024-08-20 | BVS | Buy (P) | +105,500 | $901.7K | EDGAR |
| 2024-06-13 | BVS | Grant (A) | — | $0 | EDGAR |
| 2024-06-11 | BVS | Exer (M) | +30,400 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.